Viz

Viz.ai and Vastrax Join Forces to Accelerate Clinical Trial Enrollment

Retrieved on: 
Wednesday, November 16, 2022
Technology, Biotechnology, Mobile, Wireless, Health, Apps, Applications, Pharmaceutical, Surgery, Artificial Intelligence, Medical Devices, Software, Networks, Hospitals, Internet, Data Management, Hospital, Workflow, AI, Clinical trial, State, Partnership, Algorithm, Biomedical sciences, Machine learning, State university system, Research, Safety, Physician, Disease, Acceleration, Neuro, Organization, Diagnosis, Data management, Viz, Biostatistics, Patient, Medical imaging, Pharmaceutical industry, Medical device

Together, Viz.ai and Vastrax will accelerate clinical trial enrollment for research on novel neurovascular therapies.

Key Points: 
  • Together, Viz.ai and Vastrax will accelerate clinical trial enrollment for research on novel neurovascular therapies.
  • VizTM RECRUIT software, which has demonstrated 3x1 acceleration in clinical trial enrollment, will become Vastraxs AI-powered clinical trial recruitment platform for its neurovascular trials.
  • Viz.ais cloud-based technology broadens the recruitment funnel in both size and diversity, and streamlines the trial enrollment workflow.
  • We are pleased to partner with Vastrax to advance important clinical research, said Jayme Strauss, chief clinical officer at Viz.ai.

New Study Finds 85% of Aneurysms Identified by Viz™ ANEURYSM had not Been Referred for Neurovascular Review

Retrieved on: 
Thursday, November 10, 2022
Technology, Medical Devices, Hospitals, Clinical Trials, Software, Health, General Health, Data Management, Artificial Intelligence, Hospital, Rupture, Multimedia, Aneurysm, Neurology, Diagnosis, Assistant, Viz, AI, Machine learning, McGovern Medical School, Disease, Patient, CTAS, Algorithm, Interventional Neuroradiology, University of Texas Health Science Center at Houston, Society, MD, Stroke, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20221110005419/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221110005419/en/
    Mobile viewer screen shots of Viz ANEURYSM.
  • Source: Viz.ai
    After screening nearly 1,200 computed tomography angiograms (CTAs) for stroke evaluation across eight stroke centers across Texas with Viz ANEURYSM, a total of 85% of the aneurysms detected by Viz ANEURYSM had not been previously referred for follow-up.
  • "This real-world clinical evidence validates the impact of Viz ANEURYSM in a large study.
  • For more information on the study results and Viz ANEURYSM, please join a webinar on Tuesday, November 29th at 6pm ET.

Viz.ai Launches AI-Powered VizTM Cardio Suite

Retrieved on: 
Friday, November 4, 2022
Apps, Applications, Technology, Medical Devices, Hospitals, Health Technology, Cardiology, Radiology, Health, Artificial Intelligence, American Heart Association, Therapy, Pulmonary embolism, Algorithm, Hospital, Cardiology, Multimedia, Neurology, AI, Degenerative disease, FDA, Death, Stroke, Massachusetts General Hospital, Viz, Machine learning, CEO, Completeness, Interventional cardiology, Cardiovascular disease, Partnership, Intervention, Disease, Technology, Atrial fibrillation, AHA, Diagnosis, Patient, HEART, Medical device, Medical imaging, Pharmaceutical industry

Announced during the American Heart Association (AHA) Scientific Sessions, Viz Cardio Suite leverages AI-powered disease detection, workflow optimization, and care team coordination to provide efficiencies in the delivery of cardiovascular care.

Key Points: 
  • Announced during the American Heart Association (AHA) Scientific Sessions, Viz Cardio Suite leverages AI-powered disease detection, workflow optimization, and care team coordination to provide efficiencies in the delivery of cardiovascular care.
  • Both are part of the comprehensive Viz Cardio Suite designed to speed and improve patient access to innovative cardiovascular treatments.
  • With its Cardio Suite, Viz.ai is streamlining care pathways by improving patient identification, developing disease-specific workflows and connecting patients to the right provider in their medical journey.
  • Not only does the Viz Cardio Suite leverage AI to detect more disease in more patients, but it also accelerates the care pathway.

Viz.ai Names Jieun Choe Chief Marketing Officer

Retrieved on: 
Tuesday, October 25, 2022
Technology, Medical Devices, Hospitals, Health Technology, Cardiology, Software, Health, Pharmaceutical, Artificial Intelligence, Disease, Growth, Business administration, Diagnosis, Machine learning, Master of Business Administration, IPO, Economics, Patient, Hospital, Business, Multimedia, Master, Guidant, Marketing, Viz, AI, CMO, Stanford University, Public policy, Solution, Algorithm, Management, Certara

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO).
  • Choe will report to CEO Chris Mansi, overseeing global marketing strategy, brand and communications, product marketing and demand generation.
  • Choe was most recently chief strategy and marketing officer at Certara, a global leader in biosimulation, where she headed the global marketing team and drove the strategic planning process.
  • I am thrilled to join Viz.ai as it embarks on its next stage of growth, said Choe.

Viz.ai Receives FDA 510(k) Clearance for Automated RV/LV Analysis Algorithm

Retrieved on: 
Thursday, September 1, 2022
Technology, Medical Devices, FDA, Hospitals, Health Technology, Cardiology, Software, Health, Artificial Intelligence, Massachusetts General Hospital, Machine learning, Diagnosis, Decision-making, PE, EMEA, Food and Drug Administration, Time, Interventional cardiology, Forbes, Heart, CT, Food, Intervention, Hospital, Deep learning, LV, FDA, Communication, Embolism, Algorithm, Triage, AI, Viz, Patient, Medical device, Medical imaging

Viz.ai , the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless new component of the Viz PE Solution .

Key Points: 
  • Viz.ai , the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless new component of the Viz PE Solution .
  • Automating this key patient risk indicator will enable care teams to respond more quickly than before.
  • Diagnosis and care coordination for patients suffering from PE requires fast multi-disciplinary communication for risk stratification and decision making.
  • With this clearance, the Viz PE Solution now includes both detection of clot in the lungs and degree of strain on the right heart.

Viz.ai Receives FDA 510(k) Clearance for Viz SDH

Retrieved on: 
Wednesday, July 27, 2022
Health, FDA, Medical Devices, Technology, Hospitals, Software, Artificial Intelligence, Subdural hematoma, Algorithm, Diagnosis, Intelligence, Physician, Health informatics, Food and Drug Administration, Chaman, Food, Doctor of Philosophy, Hospital, Associate, Informatics, Medicare, SUNY, SDH, EMEA, Triage, Epidural hematoma, Machine learning, Ageing, Viz, Cerebrovascular disease, Disease, FDA, MD, State university system, Patient, Forbes, Workflow, AI, State, Medical device, Neurosurgery, Buffalo, Health, FDA, Medical Devices, Technology, Hospitals, Software, Artificial Intelligence

Viz.ai , the leading AI-powered disease detection and intelligent care coordination platform, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural (SDH).

Key Points: 
  • Viz.ai , the leading AI-powered disease detection and intelligent care coordination platform, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz Subdural (SDH).
  • The Viz SDH algorithm uses artificial intelligence to automatically detect subdural hemorrhage, enabling physicians to triage patients effectively and deliver optimal care.
  • Viz SDH allows us to detect both acute and chronic subdural hemorrhages to better identify early treatment pathways.
  • The Viz SDH module is another of the fast-growing number of FDA cleared AI algorithms on the enterprise-wide Viz Platform, which is clinically validated and reimbursed by Medicare and proven to save time, improve patient outcomes and access to care.

Viz.ai Receives FDA 510(k) Clearance for Viz ANEURYSM

Retrieved on: 
Thursday, February 24, 2022
Data Management, Health, FDA, Technology, Other Technology, Pharmaceutical, Biotechnology, Medicare, Silicon, Innovation, Forbes, Diffusion, Population, Regulation of tobacco by the U.S. Food and Drug Administration, University of Toronto, Intracranial hemorrhage, University, Deep learning, Viz, Rupture, Aneurysm, Data analysis, CTAS, De novo, Stroke, CRV, ICH, Scale Venture Partners, Food, Artificial intelligence, Subarachnoid hemorrhage, FDA, Patient, GV (company), Eric Schmidt, Insight Partners, Food and Drug Administration, Mortality, Pulmonary embolism, Hospital, Medical device

Viz.ai , the world leader in artificial intelligence (AI) powered care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM.

Key Points: 
  • Viz.ai , the world leader in artificial intelligence (AI) powered care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM.
  • Viz ANEURYSM will serve as a first of its kind population health tool to facilitate population screening and enhanced care management.
  • A third FDA clearance was received in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging.
  • Also in 2021, the FDA cleared the Viz PE and Viz Aortic modules, making the Viz Platform multi-disciplinary.

New Data Presented at ISC 2022 Further Validates Impact of the Viz Platform for Intelligent Care Coordination in the Real World

Retrieved on: 
Friday, February 11, 2022
Software, Other Health, General Health, Radiology, Data Management, Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Cardiology, Biotechnology, Health, CTA, Patient, Food, Health, De novo, Poster, Mount Sinai Hospital, Viz, Triage, Mount Sinai Hospital (Manhattan), Stroke, Insight Partners, UCSD, Outcome, DTG, Radiology, Ohio State University, Bleeding, Silicon, LVO, University of California, San Diego, Regulation of tobacco by the U.S. Food and Drug Administration, Forbes, CSC, Diffusion, Intelligence, Scale Venture Partners, Ambient occlusion, GV (company), FDA, Deep learning, San Diego, Â, NPV, ISC, Overalls, ICH, Workflow, Groin, ICA, Conference, University, CRV, Intracranial hemorrhage, M1, Eric Schmidt, Medical device, Medical imaging

Data from several new studies presented this week at the American Heart Association International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ais intelligent care coordination platform for stroke in real world settings across multiple commercial modules.

Key Points: 
  • Data from several new studies presented this week at the American Heart Association International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ais intelligent care coordination platform for stroke in real world settings across multiple commercial modules.
  • Viz LVO is a promising AI-driven software that can reliably detect ICA-T and M1 LVOs with impressive NPV, sensitivity, and overall accuracy.
  • An additional abstract from the same center studied 682 patients analyzed with Viz ICH and found an overall accuracy of 99%.
  • Also in 2021, the FDA cleared the Viz PE and Viz Aortic modules, making the Viz Platform multi-disciplinary.

Viz.ai and TeleSpecialists Announce Strategic Partnership

Retrieved on: 
Wednesday, February 9, 2022
General Health, Health, Data Management, Technology, Software, Partner, Neurology, CRV, Medicine, Insight Partners, Scale Venture Partners, Efficiency, FDA, Technology, Patient, Deep learning, Viz, Forbes, CEO, Diffusion, Intracranial hemorrhage, Organization, Stroke, Workflow, LLC, Eric Schmidt, Physician, Telecare, Health, Telehealth, Regulation of tobacco by the U.S. Food and Drug Administration, De novo, Silicon, Food, Partnership, Communication, GV (company), MBA, Medical device

Viz.ai and TeleSpecialists, LLC have entered a strategic partnership that will bring AI-powered stroke care together with leading telestroke neurologists to optimize time to treatment and improve patient outcomes across the United States.

Key Points: 
  • Viz.ai and TeleSpecialists, LLC have entered a strategic partnership that will bring AI-powered stroke care together with leading telestroke neurologists to optimize time to treatment and improve patient outcomes across the United States.
  • This partnership will further facilitate stroke care coordination even when the patient and provider are hundreds of miles apart.
  • This strategic partnership with TeleSpecialists will further enhance intelligent care coordination for stroke patients, when every minute counts, said Dr. Chris Mansi, CEO of Viz.ai.
  • We also look forward to opportunities the partnership will present as we expand our AI portfolio into multiple medical specialties.

Viz.ai Debuts Viz ANX, the First AI-powered Cerebral Aneurysm Detection Solution at SVIN 2021

Retrieved on: 
Wednesday, November 17, 2021
Technology, Medical Devices, Hospitals, Other Technology, Clinical Trials, Cardiology, Software, Biotechnology, Health, Data Management, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Rupture, Physician, Society, Silicon, Neuroradiology, MMA, Triage, Aneurysm, Medtronic, Food, Stroke, Forbes, Diffusion, CEO, Bleeding, Neuroscience, Hospital, GV (company), Scale Venture Partners, Research, LES, Subdural hematoma, Grady Memorial Hospital, CTAS, CRV, Insight Partners, Annual general meeting, SDH, FDA, Multimedia, Intelligence, Patient, De novo, Safety, Technology, Deep learning, Anatomy, Federal Food, Drug, and Cosmetic Act, Intracranial aneurysm, Cuban Neuroscience Center, Intracranial hemorrhage, Veni, vidi, vici, 3D, Health, Viz, Eric Schmidt, Medical device, Medical imaging

The Viz Platform is now utilized in over 850 hospitals across the U.S. and Europe and touches almost two patients every minute.

Key Points: 
  • The Viz Platform is now utilized in over 850 hospitals across the U.S. and Europe and touches almost two patients every minute.
  • Cerebral aneurysm is challenging to detect and treat because current care pathways are complex and rely on manual identification and triage.
  • Viz.ai will showcase the new Viz ANX and Viz SDH, along with the rest of the Viz Intelligent Care Coordination Platform, at SVIN 2021.
  • Also in 2021, the FDA cleared the Viz PE and Viz Aortic modules, making the Viz Platform multi-disciplinary.